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Abstract
Heat-shock proteins are highly immunogenic. Com-
plexed with an antigen, they act as adjuvants, inducing a
humoral and cellular immune response against both the
antigen and the chaperone. In this study, we produced
an Hsp70-supported vaccine to induce the generation of
antibodies against amyloid-ß (Aß) peptides, the major
constituent of ß-amyloid plaques in Alzheimer’s disease.
The vaccine consisted of synthetic human Aß42 covalent-
ly cross-linked with DnaK, an Hsp70 homolog of Escheri-
chia coli. Active immunization of mice with this vaccine
resulted in the generation of antibodies against Aß, that
were detectable in sera after the first booster immuniza-
tion. Antibody titers varied markedly with the genetic
background of the mice. Prophylactic short-term immu-
nization of transgenic mice (APP tg2576) before the onset
of plaques, however, did not prevent amyloid plaque
deposition. There were no differences in the plaque load
and in the level of Triton X-100-soluble Aß peptides in the
brains of immunized and control-treated transgenic
mice. Unexpectedly, the level of formic-acid soluble Aß
peptides tended to be higher in immunized mice. The
reason for the increase may be an enhanced deposition
of Aß in the small cerebral blood vessels. These data
emphasize the need for anti-Aß antibodies that remove
Aß peptides from the central nervous system without
negative side effects.
Copyright © 2004 S. Karger AG, Basel
Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly. Its neuropathological characteris-
tics include neuronal loss, neurofibrillary tangles, ß-amy-
loid plaques and often congophilic angiopathy [1, 2]. The
ß-amyloid deposits consist mainly of amyloid-ß peptides
(Aß) of 40 or 42 amino acid residues [3]. For the forma-
tion of plaques, the highly amyloidogenic peptide Aß42 is
essential [4]. Aß peptides originate from the amyloid pre-
cursor protein (APP) through cleavage by ß- and Á-secre-
tases. In AD, the production of Aß exceeds its removal
from brain tissue resulting in elevated brain levels of solu-
ble or aggregated Aß42 and Aß40 [5]. Finally, the Aß aggre-
gation leads to the formation of ß-amyloid fibrils that areM.F.K. and M.H.M. contributed equally to this work.
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deposited in extracellular plaques and in walls of blood
vessels. Detergent-insoluble Aß aggregates that appear at
the onset of the disease have been suggested to exert nega-
tive effects on long-term potentiation [6] and on memory
[7]. Increased levels of brain Aß are proposed to be the
primary cause of AD [8–10]. This hypothesis is supported
by the finding that Aß fibrils precede and accelerate the
formation of neurofibrillary tangles [5, 11]. Due to the
central role of Aß peptides in AD pathology, research
focuses on inhibiting the formation of Aß or on facilitat-
ing its removal from the brain (i.e. on ß- and Á-secretase
inhibitors [12], ß-sheet inhibitors [13] or vaccines against
Aß42 [14]).
In a previous experimental vaccination, mice express-
ing an AD-related mutated human APP gene that are
characterized by amyloid pathology similar to AD
(PDAPP) have been immunized against Aß by peripheral
injections of aggregated Aß42 [14] and initial human stud-
ies showed the generation of antibodies against ß-amyloid
in patients with AD [15]. Immunization of the mice has
been shown to ameliorate the AD-like pathology. The
experiment has been repeated by many other groups in a
variety of transgenic mouse models [16, 17]. Nasal ad-
ministration of Aß peptides has also been proven effective
[18]. In addition, a soluble non-amyloidogenic, non-toxic
Aß-homologous peptide [19] or segments of the Aß pep-
tide [20] have served as immunogens. Active vaccina-
tions, as well as passive immunizations [18, 21–23], have
resulted in a reduction in the extent of ß-amyloid plaques,
or prevented plaque formation. The remaining plaques
have been found to be decorated with antibodies and sur-
rounded by activated microglia containing phagocytosed
Aß [14, 22]. These phenomena may be explained by
blocking fibril formation, clearing Aß aggregates and dis-
aggregation of amyloid fibrils [24–26] by microglial Fc-
receptor mediated phagocytosis [14, 22] or by drainage of
Aß from the cerebrospinal fluid into the blood plasma [27,
28]. The transgenic mice were partially protected from
cognitive impairment when continuously vaccinated be-
fore the onset of the disease; mice vaccinated after the
onset of disease showed an improved cognitive perfor-
mance [16, 17, 29].
In our study, we induced antibodies against Aß42 by
using the heat-shock protein (Hsp) DnaK, an Hsp70
homolog of Escherichia coli, as adjuvant and compared
this vaccine with the conventional procedure using com-
plete and incomplete Freund’s adjuvant (CFA and IFA,
respectively). Hsp are highly immunogenic and major
immunological targets during bacterial and parasitic in-
fections [30]. When complexed with another peptide or
protein, Hsp can induce humoral and cellular immune
responses against both the coupled antigen and them-
selves without the need of a classic adjuvant. This feature
of Hsp is known for several experimental vaccines against
both infections and tumors [31, 32]. The mechanism
underlying this activity of Hsp in the immune system is
hypothetical: Hsp act in a general way by inducing cyto-
kine release and expression of antigen-presenting and co-
stimulatory molecular complexes on the antigen-present-
ing cells (APC) [33, 34]. More specifically, the Hsp-anti-
gen complex may be internalized into APC with the help
of specific cellular surface receptors. After cleavage of the
substrate and translocation of the fragments into the
endoplasmic reticulum, the fragments might be displayed
on MHC class I at the surface of APCs and be recognized
by cytotoxic T cells [35]. Moreover, the antigens as exoge-
nous proteins are presented to helper T cells through
MHC class II complexes.
Materials and Methods
Mice and Materials
Female C57BL/6 mice (Harlan Laboratories, Horst, The Nether-
lands) or mice propagated from tg2576 mice expressing human APP
under the control of the prion promoter (SwAPP) [36] with an at least
50% FvB background were used in this study (kindly provided by Dr.
Karen Hsiao, Minneapolis, Minn., USA). Breeding and genotyping
of SwAPP mice were performed as described previously and accord-
ing to an approved study protocol [37]. DnaK was prepared as
described elsewhere [38]. Antibodies 6E10 (recognizes segment 1–17
of human Aß) and 4G8 (recognizes amino acid residues 17–24 of
human and murine Aß) were from Signet Laboratories (Dedham,
Mass., USA). 6H1 (recognizes amino acid residues 1–17 of human
Aß), 22C4 (recognizes amino acid residues 30–42 of human and
murine Aß) and 9G10 (recognizes amino acid residues 17–42 of
human and murine Aß) were from Evotec Neurosciences (Hamburg,
Germany). Polyclonal rabbit anti-DnaK antibodies were a gift from
Dr. Hans-Joachim Schönfeld, Hoffmann-La Roche, Basel, Switzer-
land. Peptide Aß42, the DC Protein Assay, Tricine 10–20% gels and
Tris-glycine 8% gels were purchased from Bachem (Bubendorf, Swit-
zerland), BioRad (Munich, Germany) and Invitrogen (Basel, Swit-
zerland), respectively.
Vaccine Preparation and Immunization Procedure
Before each set of intraperitoneal injections, human Aß42 was
freshly dissolved in 4.1% (v/v) aqueous triethylamine (final concen-
tration 1 mg Aß42/600 Ìl) and lyophilized to remove contaminating
ammonia. This procedure was performed twice. Phosphate-buffered
saline (PBS; 137 mM NaCl, 2 mM KCl, 12 mM sodium phosphate,
pH 7.4) was added to the lyophilized Aß42 (final concentration
444 ÌM ). The suspension was vortexed, incubated overnight at
37°C and ultrasonicated 4 times for 30 s. Glutaraldehyde (0.02%
v/v) was then added. After 2 h of gentle shaking at room temperature,
the suspension was again 4 times ultrasonicated. DnaK and PBS
were added to adjust both DnaK and Aß42 to a final concentration of
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75 ÌM. The suspension was gently shaken at room temperature for
2 h (vaccine DnaK-Aß42). The yield of cross-linking was examined
after ultracentrifugation at 100,000 g for 1 h at 4 °C. Maximally 20%
of the total DnaK remained in the supernatant. BSA plus Aß42 and
Aß42 alone were cross-linked in the same manner (vaccine BSA-Aß42
and Aß42, respectively). For the preparation of the vaccine containing
Aß42 and Freund’s adjuvant, aggregated and cross-linked Aß42 was
emulsified 1:1 (v/v) with CFA for priming, followed by boosts in IFA.
The mice received an intraperitoneal injection containing 100 Ìg
Aß42 in 300 Ìl PBS at the age of 6, 8 and 12 weeks. Blood samples
were taken at 10, 14, 18, 24, 30 and 40 weeks of age.
Determination of Antibody Titers in Sera
Blood was taken by retrobulbar punction and centrifuged in
Microtainer Brand Serum Separator Tubes (Becton Dickinson,
Franklin Lakes, N.J., USA) during 10 min with 2,000 g at 4°C. The
sera were kept at –80°C. All measurements were carried out in dupli-
cate.
For determination of anti-Aß42 antibody titers, 96-well Nunc
MicroWell plates were coated by incubation with 200 ng Aß42 in
100 Ìl PBS per well overnight at 4°C. The plates were washed 4
times with washing solution (PBS, 0.05% Tween 20), blocked with
250 Ìl blocking buffer (PBS, 0.1% Tween 20, 5% (w/v) dried milk
powder) for 2 h at 37°C. After 4 washes, sera were diluted through
1:3 dilution steps after a 1:33.3 dilution in blocking buffer up to a
dilution of 1:72,900. Each well was incubated with 200 Ìl of diluted
serum for 2 h at 37°C and then washed 5 times with washing solu-
tion. Sheep anti-mouse-Ig-HRP (Amersham; 200 Ìl per well, 1:5,000
diluted in blocking buffer) was added, the titer plate incubated for 1 h
at 37°C, and washed 5 times with washing solution. Soluble BM-
Blue POD substrate (100 Ìl; Roche) was used for the color reaction.
The absorption at 405 nm was measured after 20 min incubation at
room temperature. The titers were defined as the dilution of antise-
rum that produced 50% of the maximum signal.
Determination of the anti-DnaK antibody titer was performed in
a similar way. Nunc MicroWell plates (96 wells) were coated with
100 ng DnaK in 100 Ìl PBS during 1 h at room temperature. The
wells were washed 4 times, blocked with 250 Ìl blocking buffer for
30 min at room temperature and washed 4 times with washing solu-
tion. Mouse and control sera were prediluted 1:33.3 or 1:100 times in
blocking buffer. These diluted sera were serially diluted; at each dilu-
tion, 200 Ìl was incubated in the wells during 1 h at room tempera-
ture. After washing 5 times with washing solution, sheep anti-mouse-
Ig-HRP (Amersham; 200 Ìl per well, 1:5,000 diluted in blocking
buffer) was added to each well; the plates were incubated for 1 h at
37°C, and washed 5 times with washing solution. Soluble BM-Blue
POD substrate (100 Ìl; Roche) was added to each well and the
absorption at 405 nm measured after 10 min at room temperature.
Titers were defined as above.
Homogenization of Brain Tissue
Frontal lobes of mice (F40 mg) were triturated 15 times, first
with 22-gauge and then with 26-gauge needles in 150 Ìl lysis buffer
(250 mM sucrose, 10 mM Tris-HCl, 1% Triton X-100, pH 8.0) con-
taining 6 Ìl of 25! complete proteinase inhibitor solution (Roche).
The homogenates were centrifuged at 20,000 g during 20 min at 4°C.
The supernatant was collected and protein concentration was deter-
mined with a DC Protein Assay (Bio-Rad) and directly used for
Western blotting.
Alternatively, the frontal lobes were added to 10 volumes (w/v) of
70% (v/v) formic acid. The brains were triturated as above. The
homogenates were ultracentrifuged with 200,000 g during 1 h at 4°C.
The pellet was discarded and the supernatant neutralized through
21-fold dilution with 1 M Tris-HCl (pH 11.2). The solutions were
divided into 500-Ìl samples and stored at –20°C. The homogenates
were then either used for ELISA or for Western blotting analysis. For
Western blotting, formic acid extracts were concentrated by precipi-
tation in 10% trichloroacetic acid at –20°C. After centrifugation at
20,000 g during 10 min at 4 °C and discarding the supernatant, the
pellet was washed 3 times during 30 s with 200 Ìl acetone (–20 °C).
These washing procedures were repeated twice. The pellet was dried
with Speed Vac, dissolved and boiled in 25 Ìl 1! Lämmli buffer for
Western blotting.
Aß ELISA
Nunc MicroWell plates (96 wells) were coated with 150 Ìl 20 Ìg/
ml of monoclonal mouse antibody 22C4 directed against the COOH
termini of Aß42 and Aß40 in PBS at 4°C overnight. The plates were
blocked during 4 h at 37 °C with 250 Ìl blocking buffer (100 mM
Tris-HCl, 5 mM EDTA, 1% BSA (Sigma), 1% gelatin (Sigma), 0.1%
Tween 20, pH 7.6). After 5 times washing with PBS containing
0.02% Tween 20, the plates were stored at 4°C until further use.
Samples of 120 Ìl of the neutralized formic acid extracts were loaded
into each well of the ELISA plate and incubated overnight at room
temperature in 120 Ìl ELISA buffer (0.1 M Tris-HCl, 0.05 M EDTA,
0.05 M NaCl, 1.5% Tween 20, pH 7.2). If necessary, the samples
were adjusted to the linear range of the standard curve by dilution
with ELISA buffer. As a negative control, one sample was loaded into
an uncoated well. A standard curve was prepared with ELISA buffer
containing 0, 6.25, 12.5, 25, 50 and 100 ng Aß42 per ml. After wash-
ing 5 times with PBS, the wells were incubated with 150 Ìl of biotiny-
lated anti-Aß antibody 6E10 (1:1,000 diluted in blocking buffer) dur-
ing 20 h at room temperature. The plates were then washed 5 times
with PBS and the color reaction performed with a Vectastain ABC kit
(Vector Laboratories, Burlingame, Calif., USA) and tetramethylben-
zidine (Sigma). After 30 min, the reaction was stopped by adding
sulfuric acid and the optical density was measured at 450 nm. In
parallel, the concentrations of Aß42 were determined using a com-
mercially available kit (Innogenetics, Gent, Belgium) according to
the provider’s instructions.
Western Blotting
Samples of cellular extracts were diluted 1:1 with 2! Lämmli
buffer [39] and loaded onto a Novex 10–20% Tricine gel or an 8%
Tris-glycine gel. Electrophoresis was performed at 20 mA in 1!
Tris/Tricine (12.1 g Tris-HCl, 17.9 g Tricine, 1 g SDS per liter, pH
8.3). MultiMark® multicolored Standard LC5725 (Invitrogen)
served as marker. The proteins were blotted overnight at 4 °C and
25 mA onto a Protran BA 79 membrane (0.45 Ìm) from Schleicher
& Schuell using Towbin buffer (25 ÌM Tris-HCl, 192 ÌM glycine,
0.02% SDS, 20% methanol, pH 8.5). The membrane was cooked for
5 min in PBS and then blocked for 6 h at room temperature with
Tris-buffered saline (TBST; 100 mM Tris-HCl, 0.9% NaCl, 0.05%
Tween 20, pH 8.0) containing 5% (w/v) milk powder. Incubation
with the first antibody (either an anti-Aß42 or the anti-DnaK anti-
body), diluted in blocking buffer, was performed overnight at 4°C.
The membrane was washed 3 times with TBST and once with TBST
containing 5% (w/v) milk powder and then incubated with sheep
anti-mouse-Ig-HRP (1:2,000 diluted in blocking buffer; Amersham)
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Fig. 1. Time course of antibody titers after
immunization of C57BL/6 mice with the
DnaK-Aß42 vaccine. Mice were immunized
at 6 weeks of age and boosted 2 and 6 weeks
thereafter. A Anti-Aß42 antibody titer.
B Anti-DnaK antibody titer. Hollow circles
represent titers of single mice, full circles
represent the average. Note that the average
titers of anti-DnaK antibodies were, with the
exception of the first time point, about 10-
fold higher than the anti-Aß42 antibody ti-
ters.
for 2 h at room temperature. After washing 3 times with TBST,
detection was carried out with ECLTM Western blotting detection
reagents RPN 2106.
Immunohistology and Stereological Analysis of Amyloid Burden
in Brain
Mice were perfused with PBS. After cutting off the frontal lobe,
the remaining brain was fixed in 4% (v/v) paraformaldehyde for 48–
72 h and then embedded into paraffin. Serial 5-Ìm coronal sections
were cut throughout the neocortex. Every eighth section was immu-
nostained with antibody 4G8 yielding a total of 5–7 sections per
mouse with a 40-Ìm distance between the individual sections. As
negative controls, sections were stained with the secondary antibody
only (goat-anti-mouse IgG). Amyloid plaque burden was then esti-
mated by sampling through the neocortical region at 20! magnifica-
tion and counting the percentage of points on an overlaid grid which
were over plaques. This analysis was performed with Stereologer
Software (SPA, Alexandria, Va., USA).
Results
Generation of Antibodies
The titers of anti-Aß42 and anti-DnaK antibodies in
sera of immunized mice were determined at different
times after immunization. In a first set of experiments,
C57BL/6 mice which had been treated with the DnaK-
Aß42 construct (n = 4) showed a measurable antibody titer
against Aß42 (fig. 1A). The average titers of both anti-Aß42
and anti-DnaK antibodies (fig. 1B) increased after the
second boost to a maximum of 1,300 and 9,200, respec-
tively, and then slowly decreased to 560 and 5,200,
respectively, at the age of 40 weeks, i.e. 26 weeks after the
last booster injection. In all control groups, i.e. mice
immunized with aggregated and cross-linked Aß42 in
CFA/IFA (n = 5), BSA-Aß42 (n = 5) DnaK alone (n = 5)
and PBS (n = 5), no humoral response against Aß42 could
be detected. Anti-DnaK antibodies were generated only
Fig. 2. Time course of antibody titers after immunization of SwAPP
mice with the DnaK-Aß42 vaccine. Mice were immunized at 6 weeks
of age and boosted 2 and 6 weeks thereafter. Anti-Aß42 and anti-
DnaK antibody titers were determined in randomly selected animals
to compare the immune responses between non-transgenic and trans-
genic mice. A Anti-Aß42 antibody titer of non-transgenic mice.
B Anti-Aß42 antibody titer of transgenic mice. Hollow circles repre-
sent titers of single mice, full circles represent the average. Note that
the anti-Aß42 antibody titers in wild-type animals were about 10-fold
higher than in transgenic animals.
in mice immunized with DnaK-Aß42 or with DnaK
alone.
After the successful induction of anti-Aß42 antibodies
in C57BL/6 mice, the vaccination procedure was applied
in transgenic and non-transgenic SwAPP mice. As in the
case of C57BL/6 mice, anti-Aß42 antibodies were only
detected in animals vaccinated with the DnaK-Aß42 vac-
cine and the anti-Aß42 antibody titers increased after the
second boost in both non-transgenic and transgenic
SwAPP mice (fig. 2). In transgenic mice, the titers of both
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Fig. 3. Aß42 in brain homogenates of 6- to 9-month-old mice
detected by Western blotting. A Detection of Aß42 with antibody
6E10 (specific for human Aß) after SDS-PAGE of formic acid
extracts of mouse brains on a 8% Tris/glycine gel and Western blot-
ting. Lane 1, non-immunized non-transgenic mouse; lane 2, non-
transgenic mouse immunized with DnaK-Aß42; lane 3, non-immu-
nized transgenic mouse; lane 4, transgenic mouse immunized with
DnaK-Aß42; lane 5, transgenic mouse immunized with BSA-Aß42.
B Detection of Aß42 with antibody 9G10 (recognizes both human
and murine Aß) of formic acid extracts of mouse brains on a 10–20%
Tricine gel and Western blotting. Lane 1, Aß42 standard (5 ng); lane
2, transgenic mouse immunized with BSA-Aß42; lane 3, transgenic
mouse immunized with DnaK-Aß42; lane 4, non-immunized trans-
genic mouse; lane 5, non-transgenic mouse immunized with DnaK-
Aß42; lane 6, non-immunized non-transgenic mouse. C Detection of
Aß42 with antibody 6E10 of Triton X-100-treated mouse brains on a
10–20% Tricine gel and Western blotting. Lane 1, Aß42 standard
(5 ng); lane 2, non-immunized non-transgenic mouse; lane 3, non-
immunized transgenic mouse; lane 4, transgenic mouse immunized
with DnaK-Aß42. D Detection of Hsp70 in formic acid extracts of
mouse brains by Western blotting with anti-DnaK antibody. Lane 1,
transgenic mouse immunized with DnaK-Aß42; lane 2, non-immu-
nized transgenic mouse; lane 3, wild-type mouse immunized with
DnaK-Aß42; lane 4, non-immunized wild-type mouse.
anti-Aß42 (1,800) and anti-DnaK antibodies (3,700) were
one order of magnitude lower than in non-transgenic lit-
termates 2 weeks after the second booster injection
(13,100 and 44,000, respectively). At the age of 12–14
months, when the mice were sacrificed, none of the
DnaK-Aß42-immunized transgenic mice (n = 9) showed a
measurable anti-Aß42 titer (with one exception, a titer of
50) in contrast to the DnaK-Aß42-immunized wild-type
SwAPP mice (n = 7) which showed, at the same time, a
mean titer of 230.
Plaque Burden of the Transgenic Mice
No correlation between treatment and plaque load in
transgenic mice could be observed. At the age of 12–14
months, the majority of animals showed a low plaque bur-
den; in both the untreated (n = 4) and DnaK-Aß42-immu-
nized (n = 6) SwAPP transgenic mouse groups, there was
1 animal with a plaque load of F3%, whereas the other
members showed a level below 0.3%.
Brain Levels of Aß42
The Aß content in formic acid extracts of brains of 6-
to 9-month-old non-transgenic and transgenic immunized
or control mice was analyzed with Western blotting. At
that point in time, no or few single plaques were seen
on the histological sections of the brains. For West-
ern blotting, antibody 6E10, specific for human Aß
(fig. 3A), or 9G10, recognizing both human and murine
Aß (fig.3B), were used. DnaK-Aß42-immunized transgenic
mice showed a large band at 4 kDa corresponding to Aß,
whereas no increase in Aß was observed in the other
groups. No changes in full-length APP levels were visible.
Western blots for Aß in Triton X-100 extracts of the same
brains showed no difference in the Aß levels between the
immunized and non-immunized transgenic mouse groups
(fig. 3C). In the formic acid extracts, Hsp70 levels were
similar in all mouse groups (fig. 3D). The increase in
human Aß in brains of DnaK-Aß42-treated transgenic
mice was quantified with ELISA (fig. 4A). The Aß levels
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Fig. 4. Cerebral amyloid load determined
with ELISA. Formic acid-extracted cerebral
Aß-levels of non-immunized non-transgenic
(wt) and transgenic (tg) mice, as well as
of DnaK-Aß42-immunized non-transgenic
(i-wt) and transgenic (i-tg) mice. A 6- to
9-month-old mice. wt, n = 2; i-wt, n = 2; tg,
n = 2; i-tg, n = 3. B 12- to 14-month-old mice.
wt, n = 3; i-wt, n = 4; tg, n = 4; i-tg, n = 6.
Mean B SEM are shown.
in non-transgenic non-immunized and immunized mice,
as well as the Aß-levels in non-immunized transgenic
mice, were near the background (!3 Ìg/g brain tissue),
whereas the Aß content of the immunized transgenic ani-
mals was about 90 Ìg/g wet brain tissue.
Total Aß in formic acid extracts of brains was quantita-
tively determined by ELISA with SwAPP mice sacrificed
at the age of 12–14 months where all mice exhibited amy-
loid plaques. The cerebral levels of formic acid-extracted
total Aß (fig. 4A, B) and Aß42 (not shown) were higher in
the immunized transgenic mice than in the non-immu-
nized transgenic mice. The measurements showed clearly
higher values for the animals with high plaque load (13%;
1 animal in each group), than for the 3–5 mice per group
with low plaque load (!0.3%). Whereas in untreated
transgenic SwAPP mice, Aß was – in addition to plaques –
mainly deposited in the walls of the large cerebral blood
vessels, in the immunized transgenic mouse with a plaque
load of 3%, Aß was also found to be deposited in the small
cerebral blood vessels (fig. 5). The difference in Aß levels
of formic acid extracts between immunized and non-
immunized transgenic mice did not reach statistical sig-
nificance.
To ensure that the increase in Aß42 was not mediated
by DnaK activity or anti-DnaK antibodies, we repeated
the immunization procedure with DnaK (n = 4), Aß42 (n =
3) and DnaK-Aß42 (n = 2) as vaccines and determined the
amount of total Aß in formic acid brain homogenates
after sacrificing the mice at the age of 5–7 months. The Aß
amount in animals immunized with DnaK and Aß42 was
1.1- and 0.9-fold the level of the age-matched non-immu-
nized transgenic control, respectively. In the mice in-
jected with DnaK-Aß42, the total Aß level was 2.2-fold
higher than in the transgenic control, parallel with the
effect of immunization described above.
Discussion
This is the first study reporting the generation of anti-
bodies against Aß with DnaK, an Hsp70 homolog in
E. coli, as adjuvant. The vaccine was obtained by cross-
linking Aß42 and DnaK with glutaraldehyde following our
previously published procedure for developing antibodies
against prion protein (PrP) in wild-type mice [40]. SwAPP
mice were immunized 3 times with this vaccine several
months before the onset of ß-amyloid plaque formation.
Antibodies against Aß42 in wild-type C57BL/6 mice
were detected after the first booster injection, whereas in
control mice immunized with Aß42 in Freund’s adjuvant
no antibodies were detectable even after the second boos-
ter injection. Therefore, in our study, the DnaK-Aß42 vac-
cine was clearly superior to classic immunization with
Aß42 emulsified in Freund’s adjuvant.
The titers of both the anti-Aß42 and anti-DnaK anti-
bodies in the C57BL/6 mice were, on average, about 10
times lower than in non-transgenic C57BL/6 ! FvB
hybrid mice, suggesting a strong influence of the genetic
background on the immune response. For mice generated
by SwAPP breeding, the titers of the transgenic mice were
close to 10 times lower than those of non-transgenic litter-
mates. These results parallel reports demonstrating lower
antibody titers in transgenic mice compared with the cor-
responding wild-type animals after three inoculations of
an Aß vaccine [41]. This observation may be explained by
a tolerance phenomenon due to the overproduction of
human APP in the transgenic animals, resulting in hypo-
responsiveness to Aß of the immune system [42]. This
hyporesponsiveness seems to be due to an impaired T-cell
response, which has also been reported in AD patients
[43], rather than to B-cell tolerance. This finding was sug-
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Fig. 5. Deposition of Aß in the walls of cerebral blood vessels. Coronal section (40! magnification) stained
with 4G8 against Aß of a non-treated transgenic (A) and an immunized transgenic (B) mouse. Both mice have
a plaque load of 3% and were sacrificed at 12 months of age.
gested to be of relevance for the immunization of humans
who have elevated cerebral levels of Aß.
Despite generation of antibodies by immunization at
6, 8 and 12 weeks of age, we could not observe a protec-
tion against later plaque formation. In previous studies,
prophylactic vaccinations led to successful prevention of
plaque development [14, 16, 17]. In these studies, how-
ever, mice were continuously immunized until the ap-
pearance of plaques in the control mice, whereas in our
study we aimed to establish a vaccination procedure, fol-
lowing many commonly used vaccination protocols in
humans, with only three immunizations long before the
onset of plaque development. This procedure was shown
to be effective in generating antibodies against murine
prion protein [40]. To our knowledge, no successful pro-
phylactic immunization against ß-amyloid with only
three injections has been reported to date.
The rapid induction of antibodies against Aß42 with
our protocol is due to the specific role of Hsp in the
immune system. Despite their high structural inter-spe-
cies similarity [44], Hsp are highly immunogenic and may
serve as carrier and adjuvant when coupled with an anti-
gen [45, 46]. The high degree of sequence identity in-
cludes the risk that Hsp-containing vaccines might lead to
cross-reactivity with the host Hsp and autoimmune dis-
ease. However, healthy individuals are routinely and very
early in life primed to non-self Hsp through infections and
immunizations with vaccines containing Hsp – like those
containing Bacille Calmette-Guérin against tuberculosis
or attenuated Bordetella pertussis against whooping cough
– which lead to autoimmunity but not to autoimmune dis-
ease [47–51].
Upon active or passive vaccination, the brain levels of
Aß have been reported to be reduced [14, 19], unchanged
[16] or even increased [52]. The reasons for the discrepan-
cies may include different immunogenetic backgrounds
of the mice [20]. In our study, we observed no change in
Triton X-soluble Aß, but an increase in formic acid-
extractable Aß indicating that Aß aggregates increased in
response to DnaK-Aß42 vaccination. This trend was ap-
parent in 6- to 9-month-old mice without ß-amyloid
plaque pathology, and less marked in the 12- to 14-
month-old mice. In untreated transgenic SwAPP mice,
formic acid-soluble Aß begins to increase at this age, and
is associated with decreased detergent-soluble forms of
Aß. These detergent-insoluble forms can inhibit the for-
mation of long-term potentiation and impair learning and
memory functions [6, 7]. This change in brain Aß deposi-
tion is reported to be accompanied with only minimal Aß
deposits seen with immunohistochemistry [53].
In agreement with other studies, the amount of full-
length APP was not changed upon immunization [14, 16,
22]. The levels of murine Hsp70 remained unchanged in
all groups. The mechanism leading to the observed in-
crease in Aß levels is unknown. It is neither due to DnaK
nor to anti-DnaK antibodies, as transgenic mice immu-
nized with DnaK only did not show an increase in brain
levels of Aß; likewise, mice immunized with Aß only did
not show increased Aß levels. Thus, our results indicate a
crucial impact of the adjuvant on the biological conse-
quences of Aß vaccination. With the DnaK-Aß vaccine,
we did not observe changes in plaque burden. However,
we found an Aß deposition in the small cerebral blood
vessels in the DnaK-Aß42-immunized transgenic mouse
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with the highest plaque load (3%) in contrast to the non-
immunized transgenic littermate with the same plaque
load (fig. 5). This anecdotal finding may explain the
observed increased Aß levels after immunization and
reflect increased Aß aggregates in cerebral amyloid angi-
opathy lesions as observed in the brain blood vessels of
APP23 transgenic mice [54]. Further experimentation is
required to determine the role of various adjuvants on the
biological responses to Aß vaccination.
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